logo

For the Inventor, By the Inventor

St. Louis, MO, United States of America

Ashton T Hamme

This inventor holds 37 USPTO granted patents, primarily in Cholesterol Inhibition. Top assignees: Pharmacia Corporation, G.d. Searle & Company, Pfizer Corporation. Active years: 2002-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ashton T Hamme. Retrieved from https://idiyas.com/inventor/ashton-t-hamme

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37

% Patents Active = 8.1

Average Co-Inventor Count = 13.5

ph-index = 8

Forward Citations = 183(Granted Patents)


Location History:

  • St. Louis, MI (US) (2004)
  • Saint Louis, MO (US) (2007)
  • St. Louis, MO (US) (2002 - 2010)

Company Filing History:

goldMedal19 out of 220 
 
Pharmacia Corporation
 patents
silverMedal12 out of 1,323 
 
G.d. Searle & Company
 patents
bronzeMedal5 out of 4,488 
 
Pfizer Corporation
 patents
4. 1 out of 1 
 
Pharmacia Corporation Global Patent Department
 patent

Years Active: 2002-2010

Loading Chart...
Areas of Expertise:
Cholesterol Ester Transfer Protein
Chiral Compounds
Anticoagulants
Amino Compounds
Polycyclic Aryl
Heterocyclic Amino
Phenyl Aminoalcohol
Substituted Compounds
Selective Inhibition
Cycloalkyl Aminoalcohol
Aryl Pyridones
Diamino Compounds
37 patents (USPTO):Explore Patents
1. 7700658 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2010-04-20),
2. 7253211 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2007-08-07),
3. 7122536 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2006-10-17),
4. 6906068 - Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants (2005-06-14),
5. 6867217 - Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade (2005-03-15),
6. 6803388 - (R)-Chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-10-12),
7. 6765023 - Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-07-20),
8. 6750342 - Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade (2004-06-15),
9. 6723753 - Substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-04-20),
10. 6723752 - (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-04-20),
11. 6710089 - Substituted N-fused-phenyl-N-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-03-23),
12. 6699898 - Substituted N,N-disubstituted non-fused heterocyclo amino compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-03-02),
13. 6696472 - Substituted N-phenoxy-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-02-24),
14. 6696435 - Substituted N,N-disubstituted fused-heterocyclo amino compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-02-24),
15. 6683113 - (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-01-27),

Title: The Innovative Journey of Inventor Ashton T Hamme

Introduction:

Ashton T Hamme, a distinguished inventor based in St. Louis, MO (US), has left an indelible mark on the world of pharmaceuticals with his remarkable contributions. With an impressive portfolio of 37 patents under his name, Hamme's work has revolutionized the field of medicinal chemistry.

Latest Patents:

One of his groundbreaking inventions includes the development of (R)-chiral halogenated substituted fused heterocyclic amino compounds. These compounds have shown promising potential in inhibiting cholesterol ester transfer protein activity, thereby offering new avenues for the treatment of atherosclerosis and coronary artery diseases. Hamme's innovative processes for the preparation of these compounds have significantly enhanced their yield and stereoselectivity.

Career Highlights:

Throughout his career, Ashton T Hamme has made significant contributions to renowned companies such as Pharmacia Corporation and G.D. Searle & Company. His expertise and ingenuity have played a pivotal role in advancing the pharmaceutical industry and bringing forth novel therapeutic solutions.

Collaborations:

An inventor of Hamme's caliber does not work in isolation. He has collaborated with esteemed colleagues such as Melvin L Rueppel and Richard C Durley, whose collective efforts have led to the successful development and implementation of cutting-edge pharmaceutical technologies.

Conclusion:

In conclusion, Ashton T Hamme stands as a testament to the power of innovation and perseverance in the realm of medicinal chemistry. His relentless pursuit of excellence and unwavering commitment to scientific advancement continue to inspire generations of inventors and researchers worldwide. Hamme's legacy will undoubtedly endure as a beacon of innovation in the ever-evolving landscape of pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…